Diagnosed with Gleason 9, PSA 1.7 two months ago and adding to the replies to GabF:s post a day ago on the issue:
"Androgen deprivation therapy (ADT) might not improve survival of low-PSA, high-grade PCa, according to the investigators. For other men with Gleason 8 to 10 tumors treated with external beam radiation therapy, ADT appeared to increase survival: ADT was associated with 13% decreased risk of death from any cause when PSA values were above 2.5 ng/mL. For low-PSA, high-grade PCa patients, however, the risk of all-cause mortality increased by 36% with ADT...........
standard treatment for high-risk prostate cancer consists of radiation with long-course ADT. However, low-PSA, high-grade disease appears to be potentially resistant to hormone therapy."
from Yang DD, Mahal BAV, Sweeney C, Trinh QD, Feng FYC, Nguyen PL. Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients. 2017 ASCO Annual Meeting. J Clin Oncol 35, 2017 (suppl; abstr 5080). Poster
Besides having EBRT and brachotherapy, I am on ADT (Firmagon and Bicalutamid). Given the above apparently negative impact of ADT, does anyone have any idea whether I should consider replacing or complementing my ADT with systemic therapy?
One idea for this question arises from a post by Tall Allen, although it was not directed at low PSA. Quoting from his post: "Systemic therapies - chemo, Zytiga, Xtandi, Erleada - increases time to castration resistance and prostate cancer survival in the newly diagnosed".
My doc said the quoted study is flawed in its design and with lower levels of ADT than is now given. After five weeks of ADT and EBRT, my PSA is down to 0.14 and he says this shows my cancer is not resistant to ADT and that I should continue with this.